To construct and undertake preliminary validation of a magnetic resonance (MR) imaging scoring system designed for use in pelvic MR imaging performed for characterization of adnexal masses that were indeterminate at ultrasonography (US).
The institutional ethics committee approved this retrospective study and granted a waiver of informed consent. The study population comprised 394 women who underwent MR imaging between January 1, 2008, and October 30, 2010, for characterization of 497 adnexal masses that were seen at US. Then, masses were chronologically divided into a training set (329 masses) and a validating set (168 masses). Two radiologists who were blinded to the clinical findings retrospectively evaluated MR imaging criteria for characterization of adnexal masses. In the training set, the positive likelihood ratio (PLR) of malignancy and k values were calculated for each criterion. The reference standard was surgical pathologic findings or findings at imaging follow-up of at least 1 year. On the basis of the PLR and multivariate analysis, a five-category MR scoring system called the ADNEX MR SCORING system was created and was subsequently tested by six readers with the validating set.
Results:
There was almost perfect agreement (k . 0.80) for each MR imaging feature except for grouped septa (k = 0.558) and thickened regular septa (k = 0.555). The classification was accurate in both the training set (area under the receiver operating characteristic [ROC] curve [AUC] = 0.981 for reader 1 and 0.961 for reader 2) and the validating set (AUC = 0.964 for reader 1 and 0.943 for reader 2) . ROC curve analysis demonstrated that the optimal cutoff point was an ADNEX MR score of 3; an ADNEX MR score of 4 or higher was associated with malignancy with a sensitivity of 93.5% (58 of 62) and a specificity of 96.6% (258 of 267).
Conclusion:
In this study, a reproducible and accurate MR imaging scoring system that has the potential to improve patient care was developed and tested. Multicenter prospective validation of the score is warranted. GENITOURINARY IMAGING: An MR Imaging Scoring System for Adnexal Masses Thomassin-Naggara et al patients referred for MR imaging investigation of adnexal masses that were indeterminate at US.
Materials and Methods
The institutional ethics committee (Comité d'Ethique de la Recherche en Obstétrique et Gynécologie) approved this retrospective study and granted a waiver of informed consent.
Patients
We retrospectively queried our database and retrieved all pelvic MR imaging studies performed in female patients between January 1, 2008, and October 30, 2010 (n = 2072). Among these patients, 499 underwent pelvic MR imaging for characterization of adnexal masses that appeared complex at US. Subsequently, we excluded studies in women evaluated in the course of neoadjuvant chemotherapy (n = 7); studies in pregnant women (n = 15); studies with technical problems, including contrast material extravasation or artifacts (n = 4); and studies in which no adnexal lesion was present at MR imaging (n = 29). Fifty (10%) of 499 patients were lost to follow-up (ie, they had no available histopathologic or imaging follow-up findings) and were therefore excluded. Our final population thus comprised 394 women with 497 adnexal masses. Three tomography (CT) for the assessment of complex and indeterminate ovarian masses (6, 7) . In the literature, the accuracy of MR imaging for distinguishing malignant from benign complex adnexal masses ranges from 83% to 93% (8) (9) (10) , compared with 63%-92% with US, but depends mainly on operator expertise (9) . Recently, functional imaging techniques, including perfusion-and diffusion-weighted sequences, have allowed new criteria to be added to conventional MR imaging (11) (12) (13) , thereby improving interpretation reproducibility and the characterization of complex adnexal masses (14) . The addition of perfusion-and diffusion-weighted sequences has been shown to increase the diagnostic accuracy of conventional MR imaging in up to 25% and 15% of tumors, respectively, resulting in an overall accuracy for MR imaging greater than 90% (14) . The aim of our study was to create and validate an MR imaging scoring system to predict malignancy in O varian tumors remain the first indication for gynecologic surgery (1) . The objectives of the use of imaging techniques are to reduce the number of women unnecessarily undergoing cancer surgery, to preserve fertility in young women (by allowing laparoscopy), and, when necessary, to enable the referral of patients to a tertiary referral center with a specialist gynecologic oncologist to ensure optimal primary surgical treatment. The absence of residual tumor after primary surgery is one of the most important prognostic factors in ovarian cancer. In addition, preoperative adnexal mass characterization is important, as diagnoses based on histologic findings in intraoperative frozen sections are unreliable (2) .
Ovarian masses are first evaluated by using ultrasonography (US) (3) . In this specific setting, several authors have proposed algorithms that take into account epidemiologic characteristics, serum tumor marker levels, and US features, including the presence of solid tissue (4) . Nevertheless, in a prospective randomized trial, Yazbek et al (5) found that the diagnostic accuracy of US was operator dependent. Moreover, certain conditions that hinder accurate transvaginal examination, such as large mass size, obesity, and virginity, may be indications for magnetic resonance (MR) imaging, which is superior to computed
Implications for Patient Care
n This MR imaging scoring system (ADNEX MR SCORING system) may be used in several ways in a clinical setting: A score of 4 or greater was associated with malignancy with a sensitivity of 93.5% (58 of 62) and a specificity of 96.6% (258 of 267), so the risk of malignancy is high in patients with these scores and such patients should be referred to a cancer center, whereas when the diagnostic score is 3 or lower, the association with malignancy is minimal and the patient may benefit from more imaging follow-up or conservative treatment.
n The ADNEX MR SCORING system of adnexal masses is an MR imaging scoring system that accurately relays the radiologist's suspicions to the clinician and would help to standardize the reporting of MR imaging findings with the potential aim of improving patient care.
Advances in Knowledge
n Using the ADNEX MR SCORING system for adnexal masses, we found areas under the receiver operating characteristic curve (AUCs) for diagnosis of malignancy that were high for both the experienced and the junior reader in both the training set (AUC = 0.980 for reader 1 and 0.961 for reader 2) and the validating set (AUC = 0.964 for reader 1 and 0.943 for reader 2).
n We found that if the diagnostic score was 2, the mass had a very low (,2%) risk of being malignant.
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Then, perfusion-weighted MR images were acquired by using a dynamic contrast material-enhanced T1-weighted gradient-echo sequence that was performed through the mass at the level where a "solid tissue" had been observed on nonenhanced MR images, as previously described (17) . Solid tissue, as defined by Timmerman et al (18) , comprises vegetation, a solid portion, and irregular thickened septa (17) . This sequence was performed through the mass and the adjacent myometrium in the optimal plane. Gadolinium chelate (gadoterate meglumine, Dotarem; Guerbet, Aulnay, France) was given at a dose of 0.2 mL per kilogram of body weight by using a power injector (Medrad, Maastricht, the Netherlands) at a rate of 2 mL/sec, followed by 20 mL of normal saline to flush the tubing. Images were obtained sequentially at 2.4-second intervals beginning 10 seconds before the bolus injection, for a total of 320 seconds. Finally, delayed postcontrast axial or sagittal T1-weighted gradient-echo images were obtained systematically (with the same parameters as before injection) after gadolinium chelate injection.
MR Image Analysis
Two radiologists (I.T., with 8 years of experience in pelvic MR imaging [reader 1], and E.A., with 1 year of experience in pelvic MR imaging [reader 2]) independently reviewed the MR images in the training set. The reviewers knew the ages of the patients but were blinded to US and clinical findings. When multiple masses were present, each lesion was described, including its laterality and size. Various other criteria were also evaluated on the basis of several previously published terms ( Table 2) . A purely cystic lesion was defined by the absence of solid tissue and the absence of internal enhancement after injection and corresponded to a unilocular cyst or hydrosalpinx, both of which have low T1-weighted and high T2-weighted MR signal intensities (19) . A purely endometriotic mass was defined as a lesion that displayed high T1-weighted signal intensity that was greater than or equal to that of subcutaneous underwent MR imaging on or after March 1, 2010 (this set was called the validating set).
MR Imaging Technique
MR images were acquired with a 1.5-T MR imaging unit (Sonata, Siemens, Erlangen, Germany; or HDXT, GE Healthcare, Milwaukee, Wis) by using a pelvic phased-array coil. Patients fasted for 3 hours and received 1 mg of an antispasmodic drug (Glucagen; Novo Nordisk, Chartres, France) intravenously immediately before MR imaging to reduce bowel peristalsis.
Before gadolinium chelate injection, the following imaging sequences were performed (Table E1 [online]): sagittal and axial non-fat-suppressed T2-weighted turbo spin-echo sequences and T1-weighted gradient-echo sequences with and without fat suppression. Diffusionweighted MR images were acquired in the axial plane by using a single-shot echo-planar imaging sequence. The b values corresponding to the diffusionsensitizing gradient were 0 and 1000 sec/mm 2 . Motion-probing gradient pulses were placed in the three orthogonal planes. Isotropic diffusion-weighted images were generated by using the three orthogonal axis images. 
Overall Design of Study
Population characteristics are reported in Table 1 . The investigation was divided into two parts (15, 16) . First, data obtained in the patients who underwent MR imaging before March 1, 2010, were used to assess the performance of individual MR imaging features in classifying complex adnexal masses and to construct an MR imaging scoring system. This initial cohort, the training set, included 257 patients with 329 adnexal masses and corresponded to two-thirds of the final population. In a second step, the accuracy and reproducibility of the MR imaging scoring system were tested in the next consecutive 137 patients (with 168 adnexal lesions) who Table 1 Population Characteristics
Characteristic
Training Set (n = 257) Validating Set (n = 137) Note.-Unless otherwise specified, data are numbers of patients, with percentages in parentheses.
* Data are means 6 standard deviations.
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Purely cystic mass
Spencer et al (19) Unilocular cyst or hydrosalpinx, both of which have low T1-weighted and high T2-weighted MR signal intensities, and no internal enhancement.
Purely endometriotic mass Lesion displaying high T1-weighted signal intensity greater than or equal to that of subcutaneous fat, with shading on T2-weighted MR images and no internal enhancement.
Purely fatty mass Lesion displaying high T1-weighted signal intensity that disappeared after fat saturation and displaying no solid tissue.
Wall enhancement
Enhancement of the wall of a cyst.
Bi-or multilocularity
Timmerman et al (18) The presence of two or more septa in a cyst. (A septum is defined as a thin strand of tissue running across the cyst cavity from one internal surface to the contralateral side.)
Grouped septa
Timmerman et al (18) The presence of three or more septa close together in a part of the cyst.
Thickened regular septum or septa
Timmerman et al (18) A smooth septation with a thickness  3 mm within a cystic tissue.
Solid tissue
Timmerman et al (18) As defined by the IOTA group, solid tissue shows flow at Doppler US flow. Thus, at MR imaging, solid tissue enhances after gadolinium chelate injection. In adnexal tumors, according to the IOTA group (13), diffuse wall thickening, normal ovarian stroma, and regular septa are not considered to represent solid tissue. Thus, solid tissue is either thickened irregular septa, and/or vegetation, and/or a solid portion (including completely solid mass). Type 1 time-signal intensity curve within solid tissue Thomassin-Naggara et al (14, 17) A gradual increase in the signal intensity of the solid tissue, without a well-defined "shoulder."
Vegetations
Type 2 time-signal intensity curve within solid tissue Thomassin-Naggara et al (14, 17) A moderate initial increase in the signal intensity of solid tissue relative to that of myometrium.
Type 3 time-signal intensity curve within solid tissue Thomassin-Naggara et al (14, 17) An initial increase in the signal intensity of solid tissue that was steeper than that of myometrium.
Free fluid
Hricak et al (8) Fluid in the peritoneal cavity.
Peritoneal implants
Hricak et al (8) Nodular thickening of the peritoneum that enhances after gadolinium chelate injection.
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Mann-Whitney test was used to identify significant differences in MR imaging parameters according to lesion histopathologic type. For categoric variables, the Fisher exact test was used to identify significant differences in MR imaging parameters according to lesion histopathologic type and in the prevalence of each classification category between the training and the validating sets.
In a first step, by using MR imaging criteria, a five-category MR imaging scoring system was created. The positive likelihood ratio (PLR) of malignancy was calculated for each discriminant MR imaging criterion. On the basis of the example of the Breast Imaging Reporting and findings for 78 patients (103 lesions) and 68 patients (84 lesions), respectively (Table 3) . Among the 103 lesions in the training set evaluated with imaging follow-up at 1 year, 21 resolved and 82 were stable in size and appearance. Only one patient experienced disease progression during follow-up and underwent surgery (which revealed one mucinous borderline cystadenoma). Among the 84 lesions in the validating set evaluated with imaging follow-up at 1 year, 23 resolved and 61 were stable.
Statistical Analysis
In the training set, descriptive analysis was based on the analysis of reader 1. For continuous variables, the fat, shading on T2-weighted MR images, and no solid tissue. A purely fatty mass was defined as a lesion that displayed high T1-weighted signal intensity that decreased after fat saturation and that displayed no solid tissue. Readers also recorded enhancement of the cyst wall, bi-or multilocularity, and the presence of thickened regular septa or grouped septa (20) . The presence of a solid tissue and its morphology (18) As previously demonstrated (23), we described lesions that displayed both low T2 and b = 1000 sec/mm 2 -weighted signal intensity within the solid tissue. Finally, each reader independently analyzed the perfusion-weighted images at a standard workstation by using the breast or prostate perfusion tool and selecting two regions of interest-one in the external myometrium and one in the most enhancing part of any solid tissue. We classified the enhancement of the solid tissue by using a previously published time-signal intensity curve classification (17) . A gradual increase in the signal intensity of the solid tissue, without a well-defined "shoulder," was defined as curve type 1. A moderate initial increase in the signal intensity of solid tissue relative to that of myometrium, followed by a plateau, was defined as curve type 2. An initial increase in the signal intensity of solid tissue that was steeper than that of myometrium was defined as curve type 3 ( Fig E1 [online] ). Finally, the presence of free fluid and peritoneal implants was also noted.
Reference Standard
For the training and validating sets, final diagnoses were established by means of surgical pathologic results for 179 patients (226 lesions) and 69 patients (84 lesions), respectively, or on the basis of 1-year MR imaging or US follow-up 
Results

Interobserver Agreement
There was fair agreement for grouped septa (k = 0.558) and thickened regular septa (k = 0.555). For the 15 other MR imaging criteria, interobserver agreement was almost perfect (k = 0.801-0.960) ( Table 4) .
Pelvic Mass Characterization
All MR imaging features were discriminant in the assessment of malignancy except the following four: bilaterality (P = .07), thickened regular septa (P = .94), curve type 2 (P = .42), and the presence of free fluid (P = .006) ( Table 5) .
The criteria most highly predictive of malignancy were curve type 3 (PLR of malignancy = ∞), peritoneal implants (PLR of malignancy = 111.97), and the presence of thickened irregular septa (PLR of malignancy = 9.83) Table 6 ). The criteria most highly predictive of benignity were purely cystic mass (PLR of malignancy = 0), purely endometriotic mass (PLR of malignancy = 0), purely fatty mass (PLR of malignancy = 0), the absence of wall enhancement (PLR of malignancy = 0), low T2-weighted and b = 1000 sec/mm 2 -weighted signal intensity within solid tissue (PLR of malignancy = 0), curve type 1 within solid tissue (PLR of malignancy = 0.02), low T2-weighted signal intensity within solid tissue (PLR of malignancy = 0.03), low b = 1000 sec/mm 2 diffusion-weighted signal intensity within solid tissue (PLR of malignancy = 0.07), and the absence of solid Minn), implemented in the R programming language, was used to generate the interpretation models depicting the classification rules generated through recursive partitioning. When growing each "tree," we assigned equal prior probabilities to the two cohorts (benign vs malignant) and equal misclassification costs (25) . A true-positive finding was defined as a malignant lesion that was correctly classified, and a true-negative finding was defined as a benign lesion that was correctly classified. A false-positive finding was defined as a benign lesion that was incorrectly classified, and a false-negative finding was defined as a malignant lesion that was incorrectly classified.
In a second step, the two radiologists used this scoring system to classify adnexal masses in the training and validating sets. A receiver operating characteristic (ROC) curve analysis was performed to compare the results of interpretations by the two readers in both sets.
In a third step, four additional readers (two senior radiologists [including A.J.] and two junior radiologists, with 6 years [A.J.], 10 years, 1 year, and 1 year of experience in pelvic MR imaging, respectively)-readers 3-6, respectively-were trained in the scoring system by using cases in the training set (n = 20). Then, they independently tested the accuracy and reproducibility of the MR imaging scoring system in the validating set. Among these four additional readers, three work in other institutions. All of these readers were also blinded to all previous US and MR imaging reports and to all clinical information except patient age.
Using these additional readings, we tested the reproducibility between the readers and the discrimination between benign and malignant lesions with the ADNEX MR SCORING system of each reader and performed a calibration to test the potential clinical impact of this scoring system. Linear and quadratic k coefficients were calculated to assess interobserver agreement between the two main readers for lesion characterization and MR scoring classification, respectively, by using the following scale: Scores of 0.00-0.20 indicated slight agreement; scores of 0.21-0.40, fair Data System (BI-RADS) classification scheme used for breast tumors (24), we created an MR imaging scoring system with the following five categories: A score of 1 indicated that no mass was found at MR imaging; a score of 2 indicated a benign mass, with a PLR of malignancy of 0; a score of 3 indicated a probably benign mass, with a PLR of malignancy of less than 0.1; a score of 4 indicated an indeterminate mass, with a PLR of malignancy of 0.1-10.0; and a score of 5 indicated a probably malignant mass, with a PLR of malignancy of greater than 10.0. A multivariate interpretation model was constructed to retain only independent variables in the classification. We used a recursive partitioning program to determine for each MR imaging characteristic a cutoff point that optimally split all of the masses into benign or malignant and to select the variable that performed best. The program then takes the resulting subpopulations and repeats the process on each until no additional partitioning is warranted: Either a subpopulation contains one class of individuals or the subpopulation is too small to subdivide anew. The program RPART (Therneau and Atkinson, Mayo Clinic, Rochester, Classification MR imaging scoring system construction.-The ADNEX MR SCORING system is presented in Figure 1 and Fig E8 [online] ). The ADNEX MR SCORING system performed well, allowing a correct diagnosis in 316 of 329 masses (96%). No malignancy was given an ADNEX MR score of 2. The malignant tumors classified as having an ADNEX MR score of 3 were two borderline tumors (one serous and one mucinous), one intestinal cancer, and one undifferentiated primary invasive malignant ovarian tumor.
For readers 1 and 2, ROC curve analysis demonstrated that the optimal cutoff point was an ADNEX MR score of 3: An ADNEX MR score of 4 or greater was associated with malignancy with sensitivity of 93.5% (58 of 62) and specificity of 96.6% (258 of 267) for reader 1 and sensitivity of 90.3% (56 of 62) and specificity of 93.6% (250 of 267) for reader 2. Note.-Unless otherwise stated, data are percentages, with raw data in parentheses. The denominators used to calculate the percentages vary according to the data available.
* Data are means 6 standard deviations. † Calculated with the Mann-Whitney test; all other P values were calculated by using the Fisher exact test. GENITOURINARY IMAGING: An MR Imaging Scoring System for Adnexal Masses Thomassin-Naggara et al MR imaging scoring system validation.-At internal validation, in terms of agreement between the two readers, the reproducibility of the ADNEX MR SCORING system was almost perfect, with k = 0.892 for the training set and k = 0.888 for the validating set.
In terms of discrimination, the ADNEX MR SCORING system yielded an area under the ROC curve (AUC) of 0.981 for reader 1 and 0.961 for reader 2 in the training set; the validation set also demonstrated the good discriminatory characteristics of the ADNEX MR SCORING system, with an AUC of 0.964 for reader 1 and an AUC of 0.943 for reader 2. When applied to the validating set, the AD-NEX MR SCORING system performed well, with reader 1 correctly diagnosing 154 of 168 masses (91.7%) and reader 2 correctly diagnosing 149 of 168 masses (88.7%). There was only one false-negative reading (an AD-NEX MR score of 2 or 3) for reader 1 (one serous borderline tumor), and there were no false-negative readings (Table 8) .
At external validation, in terms of agreement between the four additional readers, the reproducibility of the AD-NEX MR SCORING system was almost perfect, with agreement ranging from 0.855 to 0.904 (Table E2 [online]).
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In terms of discrimination, the ADNEX MR SCORING system yielded AUCs of 0.980, 0.954, 0.955, and 0.973 for readers 3, 4, 5, and 6, respectively.
In terms of calibration, the probabilities of malignancy for each ADNEX MR score category and the observed frequencies are shown in Figure 4 . For all the four subsequent radiologists, the observed malignancy rates were less than 2%, less than 5%, between 5% and 58% (specifically, 58% 19] for additional readers 3-6, respectively), and more than 90% for ADNEX MR scores of 2, 3, 4, and 5, respectively. These rates were within the expected ranges observed in the training set. A lower PPV for ADNEX MR score 4 was noted for the junior readers as compared with the senior readers.
Discussion
Using MR features associated with malignancy, we developed and validated a five-category classification with an AUC higher than 0.94 in the training and validating sets. Using this classification, a small percentage of masses remained indeterminate (AD-NEX MR score 4) after MR imaging in the two cohorts.
A scoring system would be useful to standardize MR imaging reporting and thus potentially improve patient care. In the literature, various scoring systems have been developed for characterize adnexal masses on the basis of clinical criteria (eg, age, menopausal status), biochemical parameters (CA-125 levels) and US findings (4, 26, 27) . These are effective in the rapid identification of patients at high clinical risk of invasive malignancy. MR imaging has been proven to be the most accurate imaging technique and the most cost-effective intervention for categorization in women with indeterminate complex masses that are indeterminate at US (6) .
Our study shows that the ADNEX MR SCORING system is accurate, with AUCs for diagnosis of malignancy that were high (.0.94) for all readers, including experienced and junior readers. The features included in our MR scoring system are not surprising, as each has previously been used to distinguish benign from malignant masses (8) (9) (10) (11) (12) (13) 17, 23, 28) . In particular, the most statistically significant features for malignancy were curve type 3 and peritoneal implants (8) . Thus, on the basis of data in a large population, our study confirms that curve type 3, reflecting parietal immaturity, is specific for malignancy, as previously demonstrated in the epithelial subgroup (17) . Moreover, our study emphasizes that five MR criteria are very useful for ruling out malignancy in most benign cases. These criteria include purely cystic mass, purely endometriotic mass, purely fatty mass, low T2-weighted and b = 1000 sec/mm 2 -weighted signal GENITOURINARY IMAGING: An MR Imaging Scoring System for Adnexal Masses
should be referred to a cancer center. When the diagnostic score is 3 or lower, the association with malignancy is minimal, and the patient may benefit from more imaging follow-up or conservative treatment. If the diagnostic score is 2, the mass is benign, and no further investigations are necessary for characterization. Our study had several limitations. First, our study included few cases of borderline ovarian tumors (12 in the training set and three in the validating set), and a subgroup analysis for this kind of tumor was not possible to distinguish them from invasive ovarian tumors. Thus, larger studies on these tumors are necessary, especially for preoperative differentiation of borderline tumors from frankly invasive within solid tissue, and absence of wall enhancement after gadolinium chelate administration. In this study, any peritoneal fluid was assessed as a potential feature for malignancy. This was a limitation of our study, because a small amount of peritoneal fluid can be a normal finding in the female pelvis and potentially explains the low value of this sign in discriminating benign from malignant masses in our study. While it is already well known that low T2-weighted and b = 1000 sec/ mm 2 -weighted signal intensities within solid tissue are useful in the description of complex adnexal masses (13, 22) , the absence of wall enhancement can be very helpful. This sign is particularly relevant in describing peritoneal inclusion cysts or endometrioma and underlines the fact that gadolinium chelate injection is necessary to completely characterize complex adnexal masses. Our study confirms that the presence of a solid tissue is not sufficient to predict malignancy, with a PLR of 4.38. In contrast, the absence of solid tissue is highly predictive of benignity (PLR of malignancy = 0.08). When a solid tissue is detected, our study confirms the usefulness of functional MR imaging sequences, including diffusion-and perfusion-weighted sequences. A curve type 1 enables a mass to be classified as ADNEX MR score 3 (17) .
Our classification system had almost perfect agreement between all readers (k . 0.80). This classification is based on reproducible MR criteria with k values that are also higher than 0.80 for all features used. Therefore, this classification could easily be generalized for use by all radiologists, whatever their degree of expertise in pelvic imaging, as a means of improving report standardization.
Finally, our ADNEX MR SCOR-ING system may potentially influence pelvic mass management. Inspired by the BI-RADS classification, our MR scoring system is based on the PLR for malignancy and thus may be used in several ways in a clinical setting: A score of 4 or greater was associated with malignancy with a sensitivity of 93.5% (58 of 62) and a specificity of 96.6% (258 of 267). Thus, the risk of malignancy is high, and the patient tumors, which is crucial when deciding whether to opt for conservative surgery (29) (30) (31) . Second, some other potentially useful features, such as CA-125 levels, were not assessed. However, it is well known that CA-125 has a low PLR for predicting malignancy (32, 33) . Third, in our study, we chose a period of 1-year follow-up stability as the reference standard. However, borderline tumors could evolve over a longer period than 1 year. Thus, in the future, the follow-up interval and the choice of modality for follow-up (clinical examination, US, or MR imaging) will need to be determined for masses classified as ADNEX MR score 3. Fourth, our study is based on an analysis of individual masses and not a single worstappearing lesion per patient. A model GENITOURINARY IMAGING: An MR Imaging Scoring System for Adnexal Masses Thomassin-Naggara et al MR imaging features helps predict the final diagnosis. This scoring system would help to standardize MR imaging reporting with the aim of improving patient care.
examinations were performed at a single institution and may not reflect how MR imaging examinations are performed elsewhere. Referrals for MR imaging were based on the presence of indeterminate masses at US, and thus predictive values found are based on the population studied and would differ in regions where referral patterns differ. Thus, the value of this scoring system needs to be confirmed in larger prospective multicenter studies.
In conclusion, this imaging scoring system accurately relays the radiologist's suspicions to the clinician. The combination of the morphologic and functional might have greater clinical utility if it derived subject-level MR scores on the basis of the most malignant-appearing lesion rather than providing scores for individual masses. However, we believed that it was important to include all available masses in the analysis so that the final model might be used to characterize multiple masses within the same woman and because factors showing strong consistency among multiple masses that all had the same score in a single woman should indeed be given more weight in a model intended for scoring multiple masses in any one woman. Finally, all MR imaging Figure 4 Figure 4: Bar graph shows the calibration process of external validation. For all the radiologists considered, the observed malignancy rates were less than 2%, less than 5%, between 37% and 58%, and more than 90% for ADNEX MR scores of 2, 3, 4, and 5, respectively. J1 PS = junior reader 1 (study reader 5), J2 SD = junior reader 2 (study reader 6), SI AJ = senior reader 1 (study reader 3), S2 VJ = senior reader 2 (study reader 4). 
